About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients

A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients

NCT00088140·15 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Conatus Pharmaceuticals Inc.

With

Idun Pharmaceuticals

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Chronic hepatitis C infection
Unsuccessful prior HCV treatment
Liver impairment (either AST or ALT 1.5-10.0 x ULN)
Alpha-fetoprotein \<= 50 ng/mL
Adequate hematologic parameters

You may not be if

Decompensated or severe liver disease
Hepatocellular carcinoma
HIV infection
Co-infection with hepatitis B virus (HBV)
Renal impairment
Pancreatitis
Use of illicit or drugs of abuse
History of alcohol abuse
Presence of clinically significant cardiac arrhythmias
If female, pregnant or lactating

The record

StatusCompleted

PhasePhase 2

Taking part204

StartedJul 2004

UpdatedAug 13, 2012

Conditions

Hepatitis C, Chronic

Where15

Mayo Clinic Hospital
Phoenix, Arizona, United States
Scripps Clinic
La Jolla, California, United States
California Pacific Medical Center
San Francisco, California, United States